PALO ALTO, Calif., May 10, 2017 /PRNewswire/ -- Varian Medical
Systems (NYSE: VAR) today announced it has received Shonin approval
from the Japanese Ministry of Health, Labor and Welfare (MHLW) to
market the ProBeam® system for proton therapy in
Japan. This approval is the latest
example of the growing worldwide interest in proton therapy as an
advanced treatment option for cancer patients. Varian will be
showcasing the ProBeam system at the Particle Therapy Co-Operative
Group (PTCOG), May 11-13, 2017 in
Yokohama, Japan.
Varian's ProBeam system is the first to offer fully-integrated
intensity modulated proton therapy (IMPT) to enable more efficient
adaptive proton therapy. Varian's pencil beam scanning technology
gives clinicians the ability to deliver the dose precisely in the
tumor to minimize dose to healthy tissue. When combined with cone
beam computed tomography (CBCT), the ProBeam system enables
advanced image-guided adaptive therapy during the course of
treatment helping to make it the most precise form of proton
therapy available.
With proton therapy, the risk of damage to healthy tissues and
potential side effects are reduced because proton beams can be
controlled so that they deposit their energy within the tumor site
rather than passing all the way through the patient. The treatment
is particularly suitable for pediatric cancer cases as well as for
adults.
"We are very pleased that the ProBeam system has now received
Shonin approval," said Moataz Karmalawy, general manager of
Varian's Particle Therapy division. "This approval is an important
step in the growing availability of proton therapy in Japan and around the world."
For more information on ProBeam, visit www.varian.com/proton
About Varian Medical Systems
Varian Medical Systems
focuses energy on saving lives and is the world's leading
manufacturer of medical devices and software for treating and
managing cancer. Headquartered in Palo
Alto, California, Varian employs approximately 6,400 people
around the world. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact
Mark Plungy
Varian Medical Systems
+1 (650) 424-5630
mark.plungy@varian.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/varian-probeam-proton-therapy-system-receives-shonin-approval-300455076.html
SOURCE Varian Medical Systems